FrankoBear 2024-08-22 09:06:21 UTC #5 That is very interesting as I respect your contributions in the forum
Surgical Interventions Several surgical interventions are approved in the treatment of obesity including devices (e.g., intragastric balloon, endoscopic sleeve gastroplasty, vagal nerve blockade, hydrogels) and surgery [e.g., laparoscopic adjustable gastric banding (LAGB), roux-en-Y gastric bypass (RYGB), biliopancreatic diversion with duodenal switch (BPD-DS)]
The SELECT trial further showed that once-weekly semaglutide reduced first-event MACE by 20% in adults with obesity and prior cerebrovascular disease, extending cardiovascular protection beyond diabetes [319, 320]
TB-500 makes more sense when: The injury is deep or hard to reach with an injection (spine, deep hip, cardiac tissue) You're dealing with multiple injuries at the same time Recovery involves systemic inflammation rather than something localized BPC-157 makes more sense when: The injury is easy to inject near (knee, shoulder, elbow, ankle) Gut healing is the main goal, since BPC-157's strongest documented effects are in the GI tract You're targeting a neurological issue through a localized administration route Neither peptide has human RCT data for musculoskeletal use yet